Skip to main content
Evidence Snapshot

Farnesyl pyrophosphate synthase

CHEMBL3693 SINGLE PROTEIN Leishmania donovani
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:33Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3693
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Farnesyl pyrophosphate synthase as ChEMBL target CHEMBL3693, mapped to UniProt Q0GKD7. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Farnesyl pyrophosphate synthase
SINGLE PROTEIN · Leishmania donovani
As of 2026-09-13
ChEMBL target ID
CHEMBL3693
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q0GKD7
Farnesyl pyrophosphate synthase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Farnesyl pyrophosphate synthase matters

As of 2026-09-13

Farnesyl pyrophosphate synthase is reviewed as Farnesyl pyrophosphate synthase (UniProt Q0GKD7); the current evidence base includes 6 approved drugs, 66 compounds, and 3 assays, with lead potency reaching pChEMBL 8.1.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 6 approved drugs, 66 compounds, and 3 assays for this target. The dominant activity type is IC50. CHEMBL192342 is the current potency anchor at pChEMBL 8.1.

Use CHEMBL192342 as the tractability anchor when discussing potency (pChEMBL 8.1).

Activity source · ChEMBL 36 via Core Engine
6 approved pChEMBL 8.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Farnesyl pyrophosphate synthase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q0GKD7, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

66
Total Compounds
3
Total Assays
6
Approved Drugs
IC50: 67.0, KI: 18.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL192342
 8.1 Ki —
No preferred name
CHEMBL4303669
 8.0 Ki Approved
No preferred name
CHEMBL923
 7.8 Ki Approved
No preferred name
CHEMBL191634
 7.8 Ki —
No preferred name
CHEMBL192043
 7.7 Ki —

Approved Drugs

Structure Compound First Approval
ZOLEDRONIC ACID
CHEMBL4303669
 2001
RISEDRONIC ACID
CHEMBL923
 1998
ALENDRONIC ACID
CHEMBL870
 1995
PAMIDRONIC ACID
CHEMBL834
 1991
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:33Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3693